Minnelide free base 

Minnelide free base is a prodrug of Triptolide (HY-32735) that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide free base promotes apoptosis^[1].

Minnelide (0-200 nM; 48 hours) free base shows significantly decreased cell viability in pancreatic cancer cell lines after treatment in the presence, but not in the absence, of phosphatase^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) free base leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors^[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) free base prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells^[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) free base causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

470.41

C₂₁H₂₇O₁₀P

1254885-39-6

C[C@@]12[C@@]34[C@]([C@@H]5C[C@@]1([H])C6=C(C(OC6)=O)CC2)(O5)[C@@H]([C@](O7)(C(C)C)[C@@H]7[C@@H]3O4)OCOP(O)(O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Noel P, et al. Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci. 2019 May;40(5):327-341.  [Content Brief]

  [2]. Chugh R, et al. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012 Oct 17;4(156):156ra139.  [Content Brief]